科学家们预测，可能会出现另一场疫情。他们已经确定了可能导致这种病毒的病毒——尽管卫生与公众服务部告诉我们，很少有针对这些病毒的抗病毒药物获得批准或正在卫生与公众事务部资助的临床试验中

安全的疫苗对于抗击从小儿麻痹症到新冠肺炎等疾病至关重要。有证据表明，目前在美国获得许可的疫苗所提供的保护超过了其潜在风险

在参加两项戒烟治疗的随机临床试验的参与者中，评估治疗和基于多巴胺功能多态性的“加性遗传疗效评分”(AGES)与首次戒烟时间和治疗结束时的点流行戒烟的关联

美国食品药品监督管理局急于批准未经证实的疟疾药物来对抗冠状病毒，这可能会破坏这种致命病毒的其他潜在治疗方法的临床试验。

最近的证据表明，在临床试验中接受治疗的癌症患者和护理提供者之间几乎没有讨论过试验结束后患者的即时需求。

遵循随机分配“金标准”的临床试验经常使用独立彩票将患者分配到治疗组和对照组。然而，独立分配可能会产生不平衡的治疗和对照组（即人口统计学显著不同的治疗和控制人群），这会降低权力。其他分配方法，如配对设计，确保了手臂之间的平衡，同时保持随机化并允许推理。

When the Max Planck Society established the Lead Discovery Center (LDC) for the development of new medicinal compounds in 2008, only a few people believed it would be successful. Ten years later, researchers at the LDC are now working on around 20 projects involving searches for new substances that can be used for medicinal purposes. One of the compounds developed at the LDC is already being tested in clinical studies on humans, while another is soon to reach this phase. Along with academic organizations and public entities such as the Max Planck Society the Helmholtz Association and the state of North Rhine-Westphalia, a number of pharmaceutical and biotech companies such as Bayer, Boehringer Ingelheim, Gruenenthal and Merck are also involved with the development of medicinal compounds at the LDC in the capacity of licensees or cooperative partners.